Michael P. Rubin

Michael P. Rubin, M.D., Ph.D. is the founder and CEO of Northpond Ventures, a formative stage venture capital fund dedicated to science and technology. Dr. Rubin’s active directorships include Mitra Biotech, DiCE Molecules, Inflammatix, Teckro, Candel, and SpeedDx. Dr. Rubin was previously co-founder and managing partner of Sands Capital Ventures, a global cross industry venture capital business, and affiliate of Sands Capital Management. Under Dr. Rubin’s leadership, SCV invested in dozens of leading startups, resulting in numerous successful businesses and exists, including but not limited to Complete Genomics (IPO), Dova (IPO), Quad Technologies (sale to Biotechne), Firefly Bioworks (sale to Abcam), and Agilis (Sale to PTC Therapeutics).

Dr. Rubin became a board-certified physician and surgeon, and completed his fellowship training at Harvard Medical School. Dr. Rubin has led multiple IRB-approved research groups, published numerous papers in refereed journals, written chapters in leading texts, conducted clinical trials on leading commercial molecules, received NIH funding for novel research, attained industry sponsored funding for original biotherapeutic investigations, presented studies at large international forums, and conducted basic science research in molecular genetics at Harvard’s Ocular Genetics Institute. Dr. Rubin also holds an MBA from The University of Massachusetts Amherst, is a CFA charterholder, earned his medical doctorate at The University of Chicago, and holds a B.S. in Electrical Engineering from The UCLA Samueli School of Engineering, where he was the student graduation speaker.